by Christopher Freeburn | February 25, 2013 12:41 pm
[1]Shares of Affymax (NASDAQ:AFFY[2]) plunged more than 85% in Monday midday trading after the company announced a recall of its anemia drug[3].
The company and its Japanese partner Takeda Pharmaceutical (PINK:TKPYY[4]), voluntarily pulled the drug after reports indicated that 0.02% of 25,000 patients receiving Omontys had suffered extreme reactions and died, Reuters noted.
Other patients were reported to have experienced strong hypersensitivity reactions — including 19 reports of anaphylaxis — to the drug. Also known as peginesatide, the medication is designed to combat anemia in adults undergoing dialysis.
In November, the U.S. Food and Drug Administration stopped production of a generic version of the anti-cholesterol drug Lipitor made by Ranbaxy Laboratories (PINK:RBXZF[5]) after glass particles were found in some shipments[6].
Shares of Takeda Pharmaceutical fell more than 2% in over-the-counter trading.
Source URL: https://investorplace.com/2013/02/anemia-drug-recalled-after-patient-deaths/
Copyright ©2024 InvestorPlace unless otherwise noted.